Frequently Asked Questions

Risk factors include age, a family history of colorectal cancer, inflammatory bowel diseases, a low-fiber diet, smoking and obesity.

Regular screenings such as colonoscopies help detect precancerous polyps, allowing for early intervention can help the detection of colorectal cancer

Targeted therapies attack specific genetic mutations (e.g., EGFR, ALK, KRAS) in cancer cells, blocking signals that promote tumor growth. These treatments are highly effective with fewer side effects than chemotherapy.  

Yes, metastatic lung cancer can cause bone pain, neurological issues (if spread to the brain), jaundice (if spread to the liver), or hormonal imbalances (paraneoplastic syndromes).

Lung cancer spreads through the lymphatic system or bloodstream, affecting lymph nodes, bones, liver, brain, and adrenal glands. Early intervention slows or prevents metastasis.

Survival rates depend on the stage and type of lung cancer. Early-stage NSCLC has a 5-year survival rate of 60-70%, while advanced-stage cases have lower survival rates. Targeted therapies and immunotherapy have improved long-term outcomes.

Yes, lung cancer is curable if detected early. Localized tumors treated with surgery, radiation, or a combination of therapies have high survival rates. Advanced-stage lung cancer can be managed with targeted treatments and immunotherapy.  

No, while smoking is the leading cause, non-smokers can also develop lung cancer due to exposure to secondhand smoke, air pollution, radon gas, asbestos, and genetic factors.  

Yes, early detection through low-dose computed tomography (LDCT) screening significantly improves survival rates, especially in high-risk individuals such as long-term smokers. Regular screenings help detect cancer before symptoms appear.